Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma

Ovarian cancer is the most common cause of gynecologic cancer death in the United States with 22,530 newly diagnosed cases and 13,980 deaths annually. There has been a miniscule, approximately 2.3% decrease, each year in the death rates from ovarian cancer over the past few decades (1). null Although most patients with advanced ovarian cancer respond to initial platinum-based chemotherapy, 70% will relapse and ultimately become resistant,...